BiotechTube
Connecta Therapeutics

Connecta Therapeutics

Barcelona, Spain· Est.
connectatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Connecta Therapeutics is a private, pre-revenue biotech founded in 2019, advancing a novel neuroplasticity modulation platform. Its lead asset, CTH120, is a first-in-class TrkB modulator that has completed a positive Phase I trial and is preparing for Phase II development in pediatric Fragile X Syndrome (FXS), supported by a €2.5M EIC Accelerator grant. The company operates as an R&D-intensive organization aiming to develop disease-modifying therapies for CNS disorders where current treatments are limited or non-existent.

Central Nervous System (CNS)Neurodevelopmental Disorders

Technology Platform

First-in-class small molecule modulators of neuroplasticity, specifically targeting the Tropomyosin receptor kinase B (TrkB) pathway to restore neuronal function in CNS disorders.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
CTH120Fragile X SyndromePhase 1

Funding History

2
Total raised:$2.5M
Seed$2M
Grant$500K

Opportunities

The primary opportunity is addressing the complete lack of disease-modifying therapies for Fragile X Syndrome, a debilitating lifelong disorder with a growing diagnosed population.
Success in FXS could validate CONNECTA's neuroplasticity platform, enabling expansion into larger adjacent CNS markets like other neurodevelopmental disorders or neurodegenerative diseases.

Risk Factors

The company faces high clinical development risk as a single-asset entity, with the upcoming Phase II trial in a fragile pediatric population being a major inflection point.
Financial risk is also significant, as the pre-revenue company will need to raise substantial capital beyond its current grant to fund late-stage trials.

Competitive Landscape

The competitive landscape for disease-modifying FXS therapies is nascent but evolving, with several biotechs investigating various mechanisms (e.g., mGluR5 antagonists, GABA modulators). CONNECTA's first-in-class TrkB modulator approach is distinct. The broader competitive threat comes from the standard of care—off-label use of generic symptomatic drugs—which sets a low efficacy bar but also a challenging commercial environment for a premium-priced therapy.

More companies in Small Molecule Drugs →More companies in Spain →